ADVM vs. ARKK

In the year-to-date period, ADVM achieves a -33.19% return, which is significantly lower than ARKK's -9.34% return. Over the past 10 years, ADVM has underperformed ARKK with an annualized return of -37.67%, while ARKK has yielded a comparatively higher 10.57% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Adverum Biotechnologies, Inc. (ADVM) and ARK Innovation ETF (ARKK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ADVM Sharpe Ratio is -0.97, which is lower than the ARKK Sharpe Ratio of 0.36. The chart below compares the historical Sharpe Ratios of ADVM and ARKK, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither ADVM nor ARKK has paid dividends to shareholders.

The maximum ADVM drawdown since its inception was -99.55%, which is greater than ARKK's maximum drawdown of -80.91%. Use the drawdown chart below to compare losses from any high point for ADVM and ARKK. For additional features, visit the drawdowns tool.

Adverum Biotechnologies, Inc. (ADVM) has a higher volatility of 26.89% compared to ARK Innovation ETF (ARKK) at 19.49%. This indicates that ADVM's price experiences larger fluctuations and is considered to be riskier than ARKK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.